Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Avient Corporation (AVNT) vs ClearPoint Neuro Inc (CLPT) Price & Performance

Avient CorporationTrade
ClearPoint Neuro IncTrade

Price performance (Past 24H)

Key statistics

Avient Corporation vs ClearPoint Neuro Inc — how do they compare? Avient Corporation trades at $35.82 (market cap $3.28B), while ClearPoint Neuro Inc trades at $15.7 (market cap $478.63M). The key difference: Avient Corporation is far larger — about 6.9× ClearPoint Neuro Inc's market cap, and Avient Corporation pays a 3.07% dividend while ClearPoint Neuro Inc pays none. Which is the better fit depends on your goals.

AVNTCLPT
Market Cap
$3.28B$478.63M
Sector
TechnologyHealth
52-Week High
$43.28$29.60
52-Week Low
$27.48$8.66
Enterprise Value
$4.78B$506.63M
Dividend Yield
3.07%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Avient Corporation

Avient Corporation (AVNT) trades at $35.57, down 1.28% with a bearish technical signal. The company shows consistent earnings beats with Q1 2026 EPS of $0.83 exceeding expectations. Fundamentals reveal a P/E of 20.79 and net income margin of 4.81%, while cash flow trends improved from -$34M in 2025 to -$28M projected for 2026. Recent developments include new product launches and ClassNK approval for Dyneema DM20 fiber, supporting growth in renewable energy markets.

AVNT presents a mixed outlook with strong analyst support (60% buy ratings) offset by near-term technical weakness. The company's innovation pipeline and cost control measures provide upside potential, though macroeconomic headwinds and competitive pressures remain key risks. Earnings growth and successful market expansion of new technologies are critical catalysts for stock performance.

ClearPoint Neuro Inc

ClearPoint Neuro (CLPT) trades at $16.51, down 5.66% on the day, with a bullish technical signal from moving averages but negative profitability. The company reported record Q1 2026 revenue of $36.97M with 25% organic device growth, though it missed EPS estimates with a $0.32 loss. Recent FDA clearance for the Velocity Alpha surgical drill and a partnership with Sungkyunkwan University highlight expansion efforts in neurosurgical navigation and drug delivery.

Outlook remains speculative with 100% analyst buy ratings anticipating gene therapy commercialization upside, but high execution and regulatory risks persist amid consistent losses and negative margins. The stock's valuation at 11.31x sales reflects growth expectations, yet cash burn from operations requires careful monitoring of financing sustainability.

Returns comparison

Trailing returns across standard periods

About Avient Corporation

Avient Corporation is a global leader in specialized and sustainable material solutions. Formed from the legacy of PolyOne and Clariant’s masterbatch business, it provides highly engineered polymer formulations, color systems, and advanced composites that enhance the performance and sustainability of products in industries like healthcare, defense, and consumer packaging.

Read more on AVNT

About ClearPoint Neuro Inc

ClearPoint Neuro provides medical devices and software for precise neurosurgical procedures. Its navigation systems allow surgeons to perform minimally invasive brain and spine surgeries with extreme accuracy.

Read more on CLPT